Earnings Call Summary | Strata Skin Sciences(SSKN.US) Q1 2024 Earnings Conference
Earnings Call Summary | Strata Skin Sciences(SSKN.US) Q1 2024 Earnings Conference
The following is a summary of the STRATA Skin Sciences, Inc. (SSKN) Q1 2024 Earnings Call Transcript:
以下是STRATA Skin Sciences, Inc.（SSKN）2024年第一季度财报电话会议记录摘要：
Financial Performance:
财务业绩：
STRATA Skin Sciences reported a dip in Q1 2024 total revenue to $6.8 million from $7.6 million in Q1 2023, impacted by deferred gross billings and lower domestic equipment revenue.
Gross profit decreased to $3.1 million year-over-year with a gross profit percentage of 45.6%.
Operating expenses reduced to $6 million in Q1 2024 from $7 million in Q1 2023, with a leaner cost structure and right-sizing efforts pushing this down.
STRATA Skin Sciences报告称，受延期总账单和国内设备收入减少的影响，2024年第一季度的总收入从2023年第一季度的760万美元下降至680万美元。
毛利同比下降至310万美元，毛利百分比为45.6％。
运营支出从2023年第一季度的700万美元减少到2024年第一季度的600万美元，而更精简的成本结构和调整规模的努力推动了这一下降。
Business Progress:
业务进展：
STRATA Skin has enhanced its XTRAC device placements and direct-to-consumer (DTC) marketing strategy, planning to increase in subsequent quarters.
The company decreased its cash burn by 41% ($1.1 million) and its operating expenses by 14% ($1 million) via effective cost control measures.
XTRAC devices base expanded with 32 devices removed and 16 placed into new accounts in Q1 2024, supplemented by a rise in the TheraClearX device base from 92 to 104 in Q1 2024.
It also extended exclusive distribution agreements with key international partners which contributes to over 50% of its international revenue.
STRATA Skin加强了其XTRAC设备投放和直接面向消费者（DTC）的营销策略，并计划在随后的季度中增加投放量。
通过有效的成本控制措施，该公司的现金消耗减少了41％（110万美元），运营支出减少了14％（100万美元）。
XTRAC的设备基础有所扩大，在2024年第一季度删除了32台设备，将16台设备存入了新账户，同时TheraclearX的设备基础在2024年第一季度从92台增加到104台。
它还延长了与主要国际合作伙伴的独家分销协议，这占其国际收入的50％以上。
More details: Strata Skin Sciences IR
更多详情： Strata 皮肤科学红外线
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多详情，请访问投资者关系网站。本文仅供投资者参考，不构成任何投资建议。
译文内容由第三方软件翻译。